The Phase 2b trial for BIIB122 missed its primary endpoint, leading Biogen and Denali to halt further development in early Parkinson's patients. This setback raises questions about the future of LRRK2 inhibitors and their competitive landscape against other therapies.
Why it matters. This failure leaves Biogen (NASDAQ: BIIB) vulnerable to competitors like Eli Lilly and their emerging Parkinson's treatments.
Our readExpect Biogen to shift focus to other assets, as this failure significantly impacts their pipeline.
Source · Endpoints News
Kelun-Biotech's experimental ADC, sac-TMT, demonstrated a 65% reduction in tumor progression in lung cancer patients, raising hopes for similar efficacy in Western populations. The study's success could bolster Merck's (NYSE: MRK) ADC portfolio amid increasing competition.
Why it matters. The study's success could bolster Merck's (NYSE: MRK) ADC portfolio amid increasing competition.
Our readMerck's partnership with Kelun could yield a lucrative ADC pipeline, especially if results translate to broader markets.
Source · Endpoints News
Recent studies suggest that weight-loss medications from Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) may hinder cancer progression. The implications for both companies could be significant as they navigate regulatory landscapes and market perceptions.
Why it matters. The implications for both companies could be significant as they navigate regulatory landscapes and market perceptions.
Our readWatch for potential regulatory challenges that could arise from this data, affecting both Lilly and Novo's market positions.
Source · Seeking Alpha Biotech
New AI-designed miniproteins precisely modulate GPCR signaling and reveal a new "receptor diversion" microscopy-based screening system for targeting receptors long considered difficult to drug. This advancement could open new avenues for drug discovery and development.
Why it matters. This advancement could open new avenues for drug discovery and development.
Our readThis AI breakthrough positions biotech firms to enhance their drug discovery processes, making GPCRs more accessible targets.
Source · GEN News